Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials

prnasiaFebruary 10, 2021

Tag: Alterity , Parkinson's , ATH434 , The Michael J. Fox Foundation , brain

PharmaSources Customer Service